Business Segments · Business combinations

Research & Development Solutions — Business combinations

Over 4 years (FY 2021 to FY 2025), Research & Development Solutions — Business combinations shows an upward trend with a 25.9% CAGR.

Analysis

StatementSegment
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2015
Last reportedQ1 2026

How to read this metric

Higher values reflect aggressive investment in expanding service capabilities or geographic reach, while lower values suggest a focus on organic growth or integration consolidation.

Detailed definition

Captures the financial impact of integrating newly acquired entities into the research and development solutions segment...

Peer comparison

Similar to acquisition-related cash outflows or integration costs reported by peer CROs and healthcare service firms.

Metric ID: iqv_segment_research_development_solutions_business_combinations

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$25.00M$135.00M$0.00$253.00M-$16.00M-$1.00M$236.00M$0.00$180.00M$1.00M$0.00$0.00$0.00$181.00M$5.00M$0.00$79.00M$323.00M$0.00$4.00M
QoQ Change+440.0%-100.0%-106.3%+93.8%>999%-100.0%-99.4%-100.0%-97.2%-100.0%+308.9%-100.0%
YoY Change-164.0%-100.7%-100.0%>999%+200.0%-100.0%-100.0%>999%+78.5%-100.0%
Range-$16.00M$323.00M
CAGR-32.0%
Avg YoY Growth>999%
Median YoY Growth-100.0%

Frequently Asked Questions

What is IQVIA's research & development solutions — business combinations?
IQVIA (IQV) reported research & development solutions — business combinations of $4.00M in Q1 2026.
What is the long-term trend for IQVIA's research & development solutions — business combinations?
Over 4 years (2021 to 2025), IQVIA's research & development solutions — business combinations has grown at a 25.9% compound annual growth rate (CAGR), from $160.00M to $402.00M.
What does research & development solutions — business combinations mean?
The financial cost or impact associated with acquiring and integrating new businesses into the R&D segment.